Bringing the health benefits of genetics to India: MedGenome

South Asians were unrepresented as genomic sequencing took off last decade. Sam Santhosh decided India needed the benefits it could bring and now his business leads the region, explains Roshni Bandesha.

In 2003, the first human genome sequencing was successfully completed – a milestone in the study of human DNA. For many, including technology entrepreneur Sam Santhosh, it was seen as an opportunity for unlocking the source code of life.

But the problem he saw in genomic study as it intensified over the next decade, was that South Asians were barely represented. With a population then of 1.3 billion, he wanted the people of India to be included in this scientific movement and experience the benefits it could bring in informing and improving medical interventions.

And so, after 20 years working in software, Santhosh founded MedGenome in 2013. With a focus on South Asia and emerging markets, his mission is to improve global health through insight into diseases at the genetic and molecular level. Today, global pharmaceutical and biotech companies depend on MedGenome for developing novel targeted therapies and faster innovation.

Building the business on three fronts

MedGenome has three business arms – diagnostics, research and data licensing – that respectively provide solutions to individual emerging consumers, global pharmaceuticals, and research organizations.

  • On the diagnostics front, MedGenome has completed more than 200,000 genomic tests to date and obtains samples from more than 550 hospitals and 6000 clinicians across India.
  • In its research, MedGenome has built the largest database of South Asian genetic variants, gathered from its genetic diagnostics work in India, research partnerships and activity as a co-founding member with GenomeAsia 100K.
  • Furthermore, MedGenome has developed an immunology platform (Modmab) and a cancer-solution platform (Oncopept) using in-house research as part of data-licensing solutions. The platforms are licensed on a subscription basis to pharmaceutical companies seeking to develop targets for medical drugs.

Over the next two to three years the company will expand its clinical genomic testing services into smaller cities across India, as well as South-East Asian and African markets, and accelerate the company’s drug discovery programs.

How MedGenome assesses its impact

In its diagnostics work and by increasing the diversity of genomic datasets, MedGenome is making medical treatments more tailored and relevant to millions of emerging consumers and reducing the burden of non-communicable disease, at lower costs.

The business measures its impact by tracking key indicators of performance in four areas: the scale of people reached, quality of products offered, affordability for low-income consumers, and good governance standards.

  • From a scale of impact perspective, MedGenome processed 90,000 samples in 2019, with 99 per cent of these coming from unique customers. It expects to reach about 300,000 customers by 2025 and expand testing into India’s smaller towns and cities, as well as South-East Asian and African markets. At a macro level, MedGenome is first to provide access to new genomic tests including NIPT, PGS, Clinical exome, Microarray, HLA typing, and MLPA, and will continue to shape genomics across India.
  • In terms of product quality, MedGenome is best in class and has strong internal clinical quality measures, with a two-step quality check at each stage of the diagnostic journey. Its processes have received third-party certification in line with global standards and it holds national and international best practice accreditations, such as US CAP accreditation, CLIA and ISO 15189 certification.
  • In terms of affordability, MedGenome ranks highly as well. Pricing of genetic tests offered by the company has been continuously reduced over the years. Keeping in mind the affordability of consumers, patients only pay full price for the first test conducted and all additional tests are discounted. In addition, test prices are expected to decrease approximately 5 per cent each year, increasing affordability. MedGenome has also provided over 20 per cent of diagnostics tests at deep discounts (more than 50 per cent) or even free of cost for underprivileged patients.
  • In terms of good governance, MedGenome adheres to best-practice governance standards and is regulated by US CAP and NABL requirements for clinical quality governance. It has a social and ethics committee and hires highly skilled professionals and train them according to international standards. At the end of 2019, about half of the company’s staff was female.

Assessing the impact on the customer’s life (via direct interviews and studies) is the next avenue of impact measurement for MedGenome. Anecdotally, it knows customers deeply value the ability of tests to shed light on critical medical illness being faced by them or their family members.

Roshni Bandesha is an associate director at LeapFrog’s Impact Labs, a research and development hub for our partner businesses.

This case study was first published on April 14th, 2020

LeapFrog Investments